Drug Discovery World

DECEMBER 4, 2023

QN-01 is currently being evaluated in the US by the FDA’s Center for Drug Evaluation and Research (CDER) and in the UK by the Medicines and Healthcare Products Regulatory Agency (MHRA). The post Inhaled smoking cessation therapy superior to other treatments appeared first on Drug Discovery World (DDW).

Therapies 130

Therapies Treatment Pharmacokinetics Clinical Development 130

Drug Discovery World

JULY 19, 2023

Germo Gericke, Ariceum Therapeutics, tells DDW’s Megan Thomas about his work in radiopharmaceuticals for the treatment of cancer and offers valuable advice to others in this field. We are developing satoreotide as a ‘theranostic’ pair for the combined diagnosis and targeted radionuclide treatment.

Research 130

Research Clinical Development Treatment Production 130

Drug Discovery World

JUNE 6, 2023

BenevolentAI, developers of AI that accelerates biopharma discovery, has delivered BEN-34712, its pre-clinical candidate for the potential treatment of amyotrophic lateral sclerosis (ALS). ” The post BenevolentAI progresses drug for the potential treatment of ALS appeared first on Drug Discovery World (DDW).

Treatment 130

Treatment Drugs Clinical Development Therapies 130

Drug Discovery World

APRIL 25, 2023

University of California researchers have dosed the second participant in their clinical trial to identify a potential cure for HIV utilising CAR-T cell therapy. The trial is the first-in-human clinical study investigating the duo CAR-T cell therapy for the treatment of HIV.

Research 130

Research Clinical Trials Therapies Clinical Development 130

Drug Discovery World

SEPTEMBER 14, 2023

6,7 “For patients with advanced UC, including FGFR-driven tumours, outcomes remain poor and treatment options are limited; therefore, there is a need for novel, targeted therapies,” said Martin Vogel, EMEA Therapeutic Area Lead Oncology, Janssen-Cilag GmbH. “We Erdafitinib for the treatment of metastatic bladder cancer. J Clin Med.

Treatment 130

Treatment Clinical Pharmacology FDA Approval Therapies 130

Drug Discovery World

DECEMBER 5, 2023

Cancer Research UK (CRUK), Cancer Research Horizons, and precision oncology company Guardant Health have launched a collaboration to advance cancer treatment. This includes the DETERMINE trial – the first UK national precision medicine trial in rare cancers, and other CRUK and Cancer Research Horizons research collaborations.

Clinical Trials 286

Clinical Trials Drugs Trials Clinical Development 286

Drug Target Review

JUNE 9, 2023

This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, unveils some ground-breaking research on T- cell therapy for cancer , which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.

Treatment 105

Treatment Packaging Clinical Research Therapies 105

Drug Discovery World

OCTOBER 19, 2022

Following the news that the number of clinical trial recruiting sites in Ukraine has dropped by half since the Russian invasion, DDW’s Diana Spencer examines clinical trial data from analytics company Phesi and speaks to Dr Olena Karpenko , Clinical Research Director at Medical Center Ok!Clinic+ Dr Olena Karpenko.

Clinical Research 130

Clinical Research Research Clinical Trials Trials 130

Drug Target Review

OCTOBER 11, 2023

More than 7,000 rare diseases – conditions that affect fewer than 1 in 2,000 people – have been identified, and1 in 17 people will develop a rare disease in their lifetime, with children disproportionately affected. Most of these conditions are genetic in origin and the majority have no effective treatment.

Disease 113

Disease Treatment Small Molecule Therapies 113

Broad Institute

NOVEMBER 2, 2023

Bayer and Broad Institute extend cancer therapy research collaboration By Corie Lok November 2, 2023 Breadcrumb Home Bayer and Broad Institute extend cancer therapy research collaboration Long-standing industry-academia collaboration has already resulted in three clinical oncology candidates.

Therapies 105

Therapies Research Small Molecule Clinical Trials 105

Drug Discovery World

APRIL 18, 2023

Avacta Group has presented pre-clinical data describing the novel pre|CISION proteasome inhibitor, AVA3996, at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Florida, US. billion by 2026, these drugs are primarily indicated for the treatment of multiple myeloma.

Therapies 242

Therapies Clinical Development Treatment Marketing 242

Drug Discovery World

JUNE 6, 2024

Professor Charles Swanton, Cancer Research UK’s chief clinician, said the melanoma trial results were “extremely impressive”, adding: “The new vaccine approach is another piece of the puzzle that will allow more patients to be cured, hopefully, or fewer patients to suffer disease relapse. months after initial treatment.

Vaccine 147

Vaccine Clinical Trials FDA Approval Research Laboratories 147

Drug Discovery World

OCTOBER 14, 2022

“We have been collaborating with Merck on PCVs since 2016, and together we have made significant progress in advancing mRNA-4157 as an investigational personalised cancer treatment used in combination with KEYTRUDA,” said Stephen Hoge, President of Moderna.

Vaccine 244

Vaccine Research Laboratories Laboratories Clinical Development 244

Drug Discovery World

FEBRUARY 26, 2024

The US Food and Drug Administration (FDA) has granted Fast Track Designation for Certa Therapeutics’ investigational therapy FT011 for the treatment of systemic sclerosis (scleroderma). The post Scleroderma drug gets fast-tracked in the US appeared first on Drug Discovery World (DDW).

Clinical Trials 130

Clinical Trials Drugs Therapies Treatment 130

Drug Discovery World

SEPTEMBER 6, 2024

Vincent Carrère, CEO of NH TherAguix, added: “This first positive step paves the way for the major next inflexion point expected in the second half of the year regarding the interim efficacy analysis of AGuIX.

Trials 130

Trials Clinical Trials Clinical Development Hospitals 130

Drug Discovery World

JULY 5, 2024

“People living with FTD-GRN have no available disease-modifying treatments and the impact of this disorder is profound for both patients and their families,” said Dr James ‘Brad’ Elder, Professor of Neurological Surgery at The Ohio State University Wexner Medical Center.

Therapies 147

Therapies Trials Clinical Trials Clinical Development 147

Drug Discovery World

JULY 26, 2023

A Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working. The drug, MOv18 IgE, was developed by researchers at King’s College London.

Clinical Trials 130

Clinical Trials Immune Response Drugs Trials 130

Drug Discovery World

MARCH 15, 2024

We are excited to begin the next phase of development with the initiation of two 28-day patient studies, the first studies of ALX-001 in people living with Alzheimer’s and Parkinson’s disease,” commented Tim Siegert, Chief Operating Officer and Co-Founder of Allyx Therapeutics. “We

Disease 130

Disease Trials Small Molecule Pharmacokinetics 130

Drug Discovery World

APRIL 17, 2024

Under the terms of the transaction agreements, Novartis will be responsible for worldwide clinical development and commercialisation of ARV-766 and will have all research, development, manufacturing, and commercialisation rights with respect to the preclinical AR-V7 programme.

Licensing 130

Licensing Licensing Clinical Development Treatment 130

Drug Discovery World

MAY 29, 2024

All 11 trial participants had experienced disease progression in prior immunotherapy treatment before joining the trial. These preliminary findings represent some of the initial positive evidence emerging from the burgeoning field of clinical research on cancer therapies leveraging gut microbiota.

Trials 130

Trials Clinical Trials Treatment Clinical Development 130

Drug Discovery World

NOVEMBER 30, 2023

Treatment with FT011 for 12 weeks resulted in a clinically meaningful improvement in 60% of patients treated with FT011 400mg and 20% of patients in the FT011 200mg group compared with 10% in the placebo group. I look forward to collaborating with the company in the FT011 development program ahead.”

Drug Trials 147

Drug Trials Trials Clinical Trials Drugs 147

Drug Discovery World

AUGUST 4, 2023

The Global Antibiotic Research & Development Partnership (GARDP) is joining forces with Indian biopharmaceutical company Bugworks Research to accelerate the development of a new broad-spectrum antibiotic compound.

Clinical Development 130

Clinical Development Hospitals Research Pharmaceuticals 130

Drug Discovery World

MARCH 26, 2024

DDW’s Megan Thomas caught up with Oliver Rausch, Chief Scientific Officer at Storm Therapeutics, following the ESMO Targeted Anticancer Therapies Congress 2024, a global meeting focusing on promising new anticancer targets and agents, focusing on those in early phase clinical development. MT: What’s next for STORM’s research?

Therapies 162

Therapies Small Molecule RNA DNA 162

Drug Discovery World

AUGUST 21, 2024

TF is a clinically validated ADC target that is highly expressed in indications such as non-small cell lung cancer, colorectal cancer, cervical cancer, oesophageal cancer, head and neck cancer, bladder cancer and certain gastrointestinal cancers, but its expression is limited in normal tissues.

Licensing 130

Licensing Licensing Clinical Development Clinical Trials 130

Drug Discovery World

AUGUST 14, 2023

Research partners in the UK are progressing their orally available small molecule cancer immunotherapy drug into clinical development as a treatment for advanced solid tumours. We hope that this EP4-targeting approach will deliver a promising route to improving treatment options for patients with a broad range of cancers.”

Trials 130

Trials Small Molecule Pharmacokinetics Clinical Trials 130

Drug Discovery World

APRIL 22, 2024

In a study published in Cell Reports , scientists at The Institute of Cancer Research, London, have uncovered how cells know what environment they are in and therefore which shape to choose. This research has given us insight into the tricks that cancer cells are using to keep growing and spreading.”

Drugs 130

Drugs Laboratories Research Clinical Development 130

Drug Discovery World

FEBRUARY 10, 2023

The research will support the clinical development of CTx001, CTx’s lead gene therapy asset for the treatment of GA, by enabling the identification of patients with complement-driven AMD for future interventional studies.

Clinical Development 130

Clinical Development Therapies Disease Treatment 130

Drug Discovery World

SEPTEMBER 4, 2023

‘Cross-over arms in oncology clinical trials: An important consideration for patients’ was published by the Cholangiocarcinoma Foundation (CCF) with the aim of opening new doors for patients with limited treatment options. This is especially true in cancers like cholangiocarcinoma, for which treatment options are severely limited.

Clinical Trials 130

Clinical Trials Trials Treatment Clinical Development 130

Drug Discovery World

JUNE 10, 2024

VALANX Biotech has reported successful in vivo results in its lead programme VLX101 for the treatment of a range of autoimmune diseases. VALANX is researching and developing protein expression systems that allow its own synthetic amino acids to be incorporated into any protein at freely selectable positions in multiple copies.

Disease 130

Disease Protein Expression Clinical Development Treatment 130

Drug Discovery World

MARCH 5, 2024

In her day-to-day role, she is responsible for the development of UCB’s epilepsy discovery strategy, working with researchers to advance understanding of epilepsies while ensuring candidates for a future clinical treatment pipeline to improve the lives of those living with the condition.

Disease 147

Disease Treatment Research Pharmaceutical Companies 147

Drug Discovery World

MARCH 28, 2023

iOnctura, a clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer, has been awarded the innovative medicine designation, the Innovation Passport, for roginolisib, for the treatment of metastatic uveal melanoma by the Medicines & Healthcare products Regulatory Agency (MHRA).

Drugs 130

Drugs Clinical Development Therapies Production 130

LifeSciVC

JULY 17, 2024

Reaching the end goal of delivering transformational new treatment options for patients can take a decade or more even when companies execute successfully and are well capitalized. The post Looking for Opportunities to Accelerate Clinical Research in Rare Diseases appeared first on LifeSciVC.

Clinical Research 45

Clinical Research Disease Research Clinical Trials 45

Drug Discovery World

FEBRUARY 10, 2023

First-line AZ treatment for adults with biliary tract cancer approved The MHRA has approved Imfinzi in combination with gemcitabine and cisplatin as a first-line treatment for biliary tract cancer. The research will support the clinical development of CTx001, CTx’s lead gene therapy asset for the treatment of GA.

Clinical Trials 130

Clinical Trials Trials Drugs Vaccine 130

The Pharma Data

SEPTEMBER 29, 2021

to enhance outcomes, new treatments which will target kidney-specific disease mechanisms are highly desired,” said Hiddo L. Christian Rommel, Member of the chief Committee of Bayer AG’s Pharmaceutical Division and Head of Research and Development.

Clinical Development 52

Clinical Development Disease Clinical Trials Trials 52

Drug Discovery World

JULY 21, 2023

The clinical development programme for resmetirom is comprised of 18 clinical studies supporting the NDA: twelve Phase I studies, two Phase II studies, and four Phase III studies. In April 2023, resmetirom was granted Breakthrough Therapy designation by FDA for the treatment of adults with NASH with liver fibrosis.

FDA 130

FDA Drugs Clinical Development Pharmaceuticals 130

Drug Discovery World

JULY 22, 2024

In addition to BSB-1001, BlueSphere has also discovered and nominated three additional miHA-targeting TCRs for clinical development, all for use in the same clinical setting as BSB-1001.

Therapies 130

Therapies Engineering Treatment Pharma Companies 130

Drug Discovery World

JUNE 27, 2023

The US Food and Drug Administration (FDA) has published new draft guidance to highlight fundamental considerations to researchers investigating the use of psychedelic drugs for the potential treatment of medical conditions, including psychiatric or substance use disorders. However, these are still investigational products.

Drug Development 130

Drug Development FDA Clinical Trials Drugs 130